egfrcancer.org
Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR
*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of brigatinib + cetuximab combo that has stabilized a triple-mutant EGFR patient with concomitant EGFR-T790M and C797S mutations. Brigatinib, the dual EGFR-ALK inhibitor, especially when used in combination of with anti-EGFR antibody, has shown to be